Medical Service, VA Boston Healthcare System, Boston, MA, USA; Brigham & Women's Hospital, Boston, MA, USA.
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Sleep Med. 2022 Aug;96:119-121. doi: 10.1016/j.sleep.2022.05.007. Epub 2022 May 16.
Obstructive sleep apnea (OSA) has been identified as a possible contributor to interstitial lung disease. While positive airway pressure (PAP) is effective therapy for OSA, it causes large increases in lung volumes during the night that are potentially deleterious, analogous to ventilator-induced lung injury, although this has not been previously studied. The goal of this study was to assess the impact of PAP therapy on four biomarkers of alveolar epithelial and endothelial injury and extracellular matrix remodeling in patients with OSA.
In 82 patients with moderate to severe OSA who were adherent to PAP therapy, surfactant protein D, osteopontin, angiopoietin-2, and matrix metalloprotease-7 were measured by ELISA in serum samples collected before and 3- to 6-months after initiation of PAP therapy.
An increase in angiopoietin-2 level of 0.28 ng/mL following PAP therapy was observed (p = 0.007). This finding was replicated in an independent sample of OSA patients. No significant change was detected in surfactant protein D, osteopontin, or matrix metalloprotease-7.
This finding raises concern for a possible adverse impact of PAP therapy on vascular endothelium.
阻塞性睡眠呼吸暂停(OSA)已被确定为间质性肺疾病的一个可能诱因。尽管正压通气(PAP)是治疗 OSA 的有效方法,但它会导致夜间肺容积大幅增加,这可能是有害的,类似于呼吸机引起的肺损伤,尽管这尚未得到先前的研究。本研究的目的是评估 PAP 治疗对 OSA 患者肺泡上皮和内皮损伤以及细胞外基质重塑的四个生物标志物的影响。
在 82 例对 PAP 治疗依从性良好的中重度 OSA 患者中,通过 ELISA 检测血清样本中表面活性剂蛋白 D、骨桥蛋白、血管生成素-2 和基质金属蛋白酶-7 在 PAP 治疗开始前和 3-6 个月后的水平。
观察到 PAP 治疗后血管生成素-2 水平增加了 0.28ng/mL(p=0.007)。这一发现在另一组 OSA 患者中得到了复制。表面活性剂蛋白 D、骨桥蛋白或基质金属蛋白酶-7 没有明显变化。
这一发现引起了对 PAP 治疗可能对血管内皮产生不良影响的关注。